Korean Circ J.  2012 Sep;42(9):595-599. 10.4070/kcj.2012.42.9.595.

The Effect of Doubling the Statin Dose on Pro-Inflammatory Cytokine in Patients With Triple-Vessel Coronary Artery Disease

• Kim YR
• Park JH
• Lee HJ
• Pyun WB
• Park SH

• KMID: 2297889
• DOI: http://doi.org/10.4070/kcj.2012.42.9.595

Abstract

BACKGROUND AND OBJECTIVES
Statin prevents atherosclerotic progression and helps to stabilize the plaque. According to a recent study, statin reduces inflammation in blood vessels. However, it has not been demonstrated to have any anti-inflammation reaction in patients who have been diagnosed as having a triple-vessel coronary artery disease (CAD).
SUBJECTS AND METHODS
This study included a total of thirty (30) patients who had been diagnosed by coronary angiogram as having a triple-vessel CAD. Patients who already had been taking statin were given doubled dosage. An interview, physical examination and blood test were performed at the beginning of this study and three months later.
RESULTS
After doubling the dose of statin, there was no statistically significant decrease in total cholesterol, low density lipoprotein-cholesterol, (increase in) high density lipoprotein-cholesterol and triglyceride in the blood test. C-reactive protein (CRP), an acute phase reactant, significantly decreased from 0.34 mg/dL at the beginning of the study to 0.12 mg/dL at the end of study (p<0.01). The interleukin-6 concentration also significantly decreased from 8.55 pg/dL to 4.81 pg/dL (p<0.001). No major cardiovascular events occurred and the dosage regimen was not modified during the close observation period. There was no difference in the symptoms of angina pectoris, established by World Health Organization Angina Questionnaires, before and after the dose increase. Liver enzymes remained within normal range with no significant increase before and after conducting this study.
CONCLUSION
Doubling the dose of statin alone significantly lowers pro-inflammatory cytokine concentration, which is closely related to the potential acute coronary syndrome, and CRP, a marker of vascular inflammation.

Keyword

Statin; C-reactive protein; Interleukin-6

MeSH Terms

Acute Coronary Syndrome
Angina Pectoris
Blood Vessels
C-Reactive Protein
Cholesterol
Coronary Artery Disease
Coronary Vessels
Hematologic Tests
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Inflammation
Interleukin-6
Liver
Physical Examination
Reference Values
World Health Organization
Surveys and Questionnaires
C-Reactive Protein
Cholesterol
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Interleukin-6

Figure

• 

  Fig. 1 Changes of C-reactive protein (A) and Interleukin-6 (B) concentrations before and after doubling the statin dose. *p<0.001, †p<0.01 denotes that the reduction was significantly different before and after doubling the dose of statin therapy.

Reference

1. Libby P, Sasiela W. Plaque stabilization: can we turn theory into evidence? Am J Cardiol. 2006. 98(11A):26P–33P.

2. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004. 350:1387–1397.

3. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008. 359:2195–2207.

4. Biloglav Z, Ivanković D, Campbell H, Rudan I. Performance of WHO Angina Questionnaire in measuring burden of coronary heart disease in human isolate populations. Coll Antropol. 2004. 28:205–213.

5. Murphy NF, Stewart S, Hart CL, MacIntyre K, Hole D, McMurray JJ. A population study of the long-term consequences of Rose angina: 20-year follow-up of the Renfrew-Paisley Study. Heart. 2006. 92:1739–1746.

6. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation: modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999. 130:461–470.

7. Mills R, Bhatt DL. The Yin and Yang of arterial inflammation. J Am Coll Cardiol. 2004. 44:50–52.

8. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001. 286:327–334.

9. Apple FS, Wu AH, Mair J, et al. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin Chem. 2005. 51:810–824.

10. Shishehbor MH, Bhatt DL, Topol EJ. Using C-reactive protein to assess cardiovascular disease risk. Cleve Clin J Med. 2003. 70:634–640.

11. Kofler S, Nickel T, Weis M. Role of cytokines in cardiovascular diseases: a focus on endothelial responses to inflammation. Clin Sci (Lond). 2005. 108:205–213.

12. LaRosa JC. Pleiotropic effects of statins and their clinical significance. Am J Cardiol. 2001. 88:291–293.

13. Shishehbor MH, Brennan ML, Aviles RJ, et al. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation. 2003. 108:426–431.

14. Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001. 344:1959–1965.

15. Morrow DA, de Lemos JA, Sabatine MS, et al. Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial. Circulation. 2006. 114:281–288.

16. Ridker PM, Morrow DA, Rose LM, Rifai N, Cannon CP, Braunwald E. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 Trial. J Am Coll Cardiol. 2005. 45:1644–1648.

17. Ambrose JA, Martinez EE. A new paradigm for plaque stabilization. Circulation. 2002. 105:2000–2004.

18. Alsheikh-Ali AA, Maddukuri PV, Han H, Karas RH. Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials. J Am Coll Cardiol. 2007. 50:409–418.

19. Wenger NK, Lewis SJ, Herrington DM, Bittner V, Welty FK. the Treating to New Targets Study Steering Committee and Investigators. Outcomes of using high- or low-dose atorvastatin in patients 65 years age or older with stable coronary heart disease. Ann Intern Med. 2007. 147:1–9.